Preclinical biotech Stoke Therapeutics plans $86M IPO
May 23, 2019 at 17:27 PM EDT
An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.
